CN117357614A - 一种改善儿童腺样体肥大的中药组合物及其应用与水煎剂、口服液和颗粒剂 - Google Patents
一种改善儿童腺样体肥大的中药组合物及其应用与水煎剂、口服液和颗粒剂 Download PDFInfo
- Publication number
- CN117357614A CN117357614A CN202311491496.2A CN202311491496A CN117357614A CN 117357614 A CN117357614 A CN 117357614A CN 202311491496 A CN202311491496 A CN 202311491496A CN 117357614 A CN117357614 A CN 117357614A
- Authority
- CN
- China
- Prior art keywords
- extract
- parts
- water
- mixing
- extracting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 54
- 201000003462 adenoid hypertrophy Diseases 0.000 title claims abstract description 32
- 239000003814 drug Substances 0.000 title claims abstract description 32
- 239000008187 granular material Substances 0.000 title claims abstract description 22
- 239000007788 liquid Substances 0.000 title claims abstract description 19
- 240000003915 Lophatherum gracile Species 0.000 claims abstract description 18
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 13
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 claims abstract description 13
- 239000000284 extract Substances 0.000 claims description 80
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 69
- 238000002156 mixing Methods 0.000 claims description 60
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 48
- 238000000605 extraction Methods 0.000 claims description 31
- 241001598107 Imperata Species 0.000 claims description 24
- 238000001694 spray drying Methods 0.000 claims description 24
- 241000205585 Aquilegia canadensis Species 0.000 claims description 15
- 235000019441 ethanol Nutrition 0.000 claims description 14
- 210000004907 gland Anatomy 0.000 claims description 14
- 241000245665 Taraxacum Species 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 12
- 240000000691 Houttuynia cordata Species 0.000 claims description 10
- 235000013717 Houttuynia Nutrition 0.000 claims description 8
- 244000046146 Pueraria lobata Species 0.000 claims description 8
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 8
- 244000185386 Thladiantha grosvenorii Species 0.000 claims description 8
- 235000011171 Thladiantha grosvenorii Nutrition 0.000 claims description 8
- 239000012141 concentrate Substances 0.000 claims description 8
- 241000213006 Angelica dahurica Species 0.000 claims description 7
- 241000756042 Polygonatum Species 0.000 claims description 7
- 239000002244 precipitate Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 244000025254 Cannabis sativa Species 0.000 claims description 6
- 241000628997 Flos Species 0.000 claims description 6
- 229940067866 dandelion extract Drugs 0.000 claims description 6
- 235000020691 dandelion extract Nutrition 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 239000001845 taraxacum officinale leaf extract Substances 0.000 claims description 6
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 5
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 5
- 240000000249 Morus alba Species 0.000 claims description 5
- 235000008708 Morus alba Nutrition 0.000 claims description 5
- 235000007516 Chrysanthemum Nutrition 0.000 claims description 4
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims description 4
- 241000758794 Asarum Species 0.000 claims description 3
- 235000008737 Polygonatum biflorum Nutrition 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 3
- 235000011477 liquorice Nutrition 0.000 claims description 3
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 2
- 235000013719 Houttuynia cordata Nutrition 0.000 claims description 2
- 239000009141 Houttuynia cordata plant extract Substances 0.000 claims description 2
- 206010020880 Hypertrophy Diseases 0.000 claims description 2
- 241001633680 Polygonatum odoratum Species 0.000 claims description 2
- 238000002386 leaching Methods 0.000 claims description 2
- 229940010454 licorice Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 240000007171 Imperata cylindrica Species 0.000 abstract 1
- 240000001949 Taraxacum officinale Species 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 34
- 230000000694 effects Effects 0.000 description 14
- 206010028748 Nasal obstruction Diseases 0.000 description 13
- 206010041235 Snoring Diseases 0.000 description 13
- 210000002534 adenoid Anatomy 0.000 description 8
- 241000321096 Adenoides Species 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 230000029058 respiratory gaseous exchange Effects 0.000 description 7
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 6
- 239000007922 nasal spray Substances 0.000 description 5
- 229940097496 nasal spray Drugs 0.000 description 5
- 210000001989 nasopharynx Anatomy 0.000 description 5
- 238000010298 pulverizing process Methods 0.000 description 5
- 230000027939 micturition Effects 0.000 description 4
- 210000001331 nose Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 229960002129 cefixime Drugs 0.000 description 3
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 3
- 229960003530 donepezil Drugs 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 2
- 208000001705 Mouth breathing Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 229960004436 budesonide Drugs 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012559 Developmental delay Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 208000016621 Hearing disease Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003097 anti-respiratory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229960001668 cefuroxime Drugs 0.000 description 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000003054 facial bone Anatomy 0.000 description 1
- 210000001097 facial muscle Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/78—Saururaceae (Lizard's-tail family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及中药技术领域,尤其涉及一种改善儿童腺样体肥大的中药组合物及其应用与水煎剂、口服液和颗粒剂。本发明提供了改善儿童腺样体肥大的中药组合物,包括如下质量份数的组分:玉竹8~15份、白芷10~14份、罗汉果6~8份、鱼腥草10~15份、蒲公英6~10份、鲜白茅根8~15份、淡竹叶5~10份。将上述组分制备成治疗儿童腺样体肥大的药物,有效率能达到88%以上,可以有效治疗和预防儿童腺样体肥大。
Description
技术领域
本发明涉及中药技术领域,尤其涉及一种改善儿童腺样体肥大的中药组合物及其应用与水煎剂、口服液和颗粒剂。
背景技术
腺样体也称增殖体,是咽淋巴环的组成部分,参与免疫反应。腺样体肥大是儿童常见疾病,以鼻塞、张口呼吸、打鼾为主要临床表现,可引起颜面骨骼、肌肉发育障碍,形成“腺样体面容”。日久导致患儿体质虚弱和智力迟钝,通常需要手术治疗。现阶段,治疗小儿腺样体肥大的主要治疗方法为手术切除腺样体,腺样体作为人体的免疫器官,免疫学认为,在小儿免疫系统充分形成期将腺样体切除,很容易对小儿抗呼吸道感染的全面免疫功能以及鼻咽部局部免疫功能造成损害。
缺乏经济安全、副作用小的药物来满足现有技术的不足,基于此提出本发明。
发明内容
本发明的目的在于提供安全、副作用小的药物来治疗儿童腺样体肥大,具体涉及一种改善儿童腺样体肥大的中药组合物及其应用与水煎剂、口服液和颗粒剂。
为了实现上述发明目的,本发明提供以下技术方案:
本发明提供了一种改善儿童腺样体肥大的中药组合物,包括如下质量份数的组分:
玉竹8~15份、白芷10~14份、罗汉果6~8份、鱼腥草10~15份、蒲公英6~10份、鲜白茅根8~15份、淡竹叶5~10份。
作为优选,包括如下质量份数的组分:
玉竹10~13份、白芷11~13份、罗汉果6.5~7.5份、鱼腥草11~14份、蒲公英7~9份、鲜白茅根10~13份、淡竹叶6~9份。
作为优选,包括如下质量份数的组分:
玉竹11.5份、白芷12份、罗汉果7份、鱼腥草12.5份、蒲公英8份、鲜白茅根11.5份、淡竹叶7.5份。
作为优选,还包括如下组分中的任意一种或多种:
甘草、桑叶、葛根、金银花和菊花;
甘草、桑叶、葛根、金银花和菊花的加量独立为2~8份。
本发明还提供了所述的中药组合物在制备改善儿童腺样体肥大的药物中的应用。
作为优选,所述药物的剂型为水煎剂、口服液或颗粒剂。
本发明还提供了一种改善儿童腺样体肥大的水煎剂,所述水煎剂由所述的中药组合物制备而成;
所述水煎剂的制备方法包括如下步骤:
将玉竹、白芷、罗汉果、鱼腥草、蒲公英、鲜白茅根、淡竹叶、桑叶和甘草混合,得到混合物;将所述的混合物与水混合,煎煮1.5~2.5h,过滤,取滤液,得到水煎剂;
所述混合物与水混合的质量比为1:7~9。
本发明还提供了一种改善儿童腺样体肥大的口服液,所述口服液由所述的中药组合物制备而成;
所述口服液的制备方法包括如下步骤:
(1)将玉竹与水混合,95~100℃提取1~3次,合并提取液,将所述的提取液浓缩至原体积的1/5~1/4,得到浓缩物;将所述的浓缩物与无水乙醇混合,静置10~14h,过滤,取沉淀;淋洗所述的沉淀2~4次后,干燥,得玉竹提取物;
(2)将罗汉果与水混合,95~100℃提取1~3次,合并提取液,将所述的提取液浓缩至60℃相对密度为1.2~1.3,得到浸膏,将所述的浸膏喷雾干燥,得到罗汉果提取物;
(3)将鱼腥草与水混合,95~100℃提取2~4次,合并提取液,将所述的提取液浓缩至60℃相对密度为1.2~1.3,得到浸膏,将所述的浸膏喷雾干燥,得到鱼腥草提取物;
(4)将蒲公英与乙醇溶液混合,加热提取3~5h,过滤,取滤渣;将所述的滤渣与水混合,提取1~3次,合并提取液,将所述的提取液浓缩至60℃相对密度为1.1~1.2的浸膏,将所述的浸膏喷雾干燥,得到蒲公英提取物;
(5)将鲜白茅根与水混合,95~100℃提取2~4次,合并提取液,将所述的提取液浓缩至60℃相对密度为1.1~1.2的浸膏,将所述的浸膏喷雾干燥,得到鲜白茅根提取物;
(6)将白芷与乙醇溶液混合,加热提取1~3次,合并提取液,将所述的提取液浓缩至60℃相对密度为1.1~1.2的浸膏,将所述的浸膏喷雾干燥,得到白芷提取物;
(7)将淡竹叶与水混合,95~100℃提取2~4次,合并提取液,将所述的提取液浓缩至60℃相对密度为1.1~1.2的浸膏,将所述的浸膏喷雾干燥,得到淡竹叶提取物;
(8)将葛根与水混合,95~100℃提取1~3次,合并提取液,将所述的提取液浓缩至60℃相对密度为1.2~1.3,得到浸膏,将所述的浸膏喷雾干燥,得到葛根提取物;
(9)将金银花与水混合,95~100℃提取1~3次,合并提取液,将所述的提取液浓缩至60℃相对密度为1.2~1.3,得到浸膏,将所述的浸膏喷雾干燥,得到金银花提取物;
(10)将所述的玉竹提取物、罗汉果提取物、鱼腥草提取物、蒲公英提取物、鲜白茅根提取物、白芷提取物、淡竹叶提取物、葛根提取物和金银花提取物混合,得到混合物,将所述的混合物与水混合,过滤,取滤液,得到口服液;
步骤(1)所述玉竹与水混合的质量体积比为1g:9~11ml;步骤(1)所述提取时,每次提取的时间为3~5h;步骤(1)所述浓缩物与无水乙醇混合的体积比为1:3~5;
步骤(2)所述罗汉果与水混合的质量体积比为1g:10~14ml;步骤(2)所述提取时,每次提取的时间为1.8~2.2h;
步骤(3)所述鱼腥草与水混合的质量体积比为1g:9~11ml;步骤(3)所述提取时,每次提取的时间为1.8~2.2h;
步骤(4)所述蒲公英与乙醇溶液混合的质量体积比为1g:9~11ml;所述乙醇溶液的初始浓度为45~55vt%;步骤(4)所述加热提取的温度为75~85℃;所述滤渣与水混合的质量体积比为1g:9~11ml;步骤(4)所述提取的温度为65~75℃;步骤(4)所述提取时,每次提取的时间为0.8~1.2h;
步骤(5)所述鲜白茅根与水混合的质量体积比为1g:2~4ml;步骤(5)所述提取时,每次提取的时间为1.8~2.2h;
步骤(6)所述白芷与乙醇溶液混合的质量体积比为1g:4~6ml;步骤(6)所述乙醇溶液的初始浓度为70~80vt%;步骤(6)所述加热提取的温度为70~80℃;步骤(6)所述加热提取时,每次提取的时间为1.8~2.2h;
步骤(7)所述淡竹叶与水混合的质量体积比为1g:6~8mL;步骤(7)所述提取时,每次提取的时间为2~3h;
步骤(8)所述葛根与水混合的质量体积比为1g:7~9ml;步骤(8)所述提取时,每次提取的时间为2.5~3.5h;
步骤(9)所述金银花与水混合的质量体积比为1g:6~8ml;步骤(9)所述提取时,每次提取的时间为1.5~2.5h;
步骤(10)所述混合物与水混合的质量体积比为1g:4~6ml。
本发明还提供了一种改善儿童腺样体肥大的颗粒剂,所述颗粒剂由所述的中药组合物制备而成;
所述颗粒剂的制备方法包括如下步骤:
将玉竹、白芷、罗汉果、鱼腥草、蒲公英、鲜白茅根、淡竹叶、金银花和菊花混合,得到混合物;将所述的混合物与水混合,95~100℃提取2~4次,合并提取液;将所述的提取液浓缩至60℃相对密度为1.2~1.3的浸膏,将所述的浸膏与药学上可接受的辅料混合,得到颗粒剂;
所述混合物与水混合的质量体积比为1g:9~11ml;所述提取时,每次提取的时间为1.8~2.2h。
本发明提供了一种改善儿童腺样体肥大的中药组合物及其应用与水煎剂、口服液和颗粒剂。
本发明的中药组合物中加入了具有安神强心、养阴润燥、生津止渴功效的玉竹;具有除湿排脓、生肌、活血止痛的白芷;润肺止咳、补充能量的罗汉果;清热去火、杀菌、利尿的鱼腥草;清热解毒、消痈散结功效的蒲公英;清热解毒、消肿利尿功效的鲜白茅根;清热泻火、除烦、利尿功效的淡竹叶。这些组分在中药组合物中起主要作用,共奏清热解毒、杀菌、利尿的功效,对于儿童腺样体肥大的有效率高达88%以上,具有很好的推广价值。
具体实施方式
下面结合实施例对本发明提供的方案进行详细的说明,但是不能把它们理解为对本发明保护范围的限定。
实施例1
称取玉竹8g、白芷12g、罗汉果6g、鱼腥草10g、蒲公英6g、鲜白茅根15g、桑叶2g、淡竹叶5g、甘草2g,混合均匀,得到混合物。将混合物与520g水混合,煎煮2h,过滤,取滤液,得到水煎剂。
实施例2
取150g玉竹,粉碎后与1500ml水混合,100℃提取4h,提取2次,合并提取液,将提取液减压浓缩至原体积的1/4,得到浓缩物。在浓缩物中加入4倍体积的无水乙醇搅拌均匀后,静置12h,过滤,取沉淀。利用无水乙醇淋洗沉淀3次,将沉淀干燥,得到玉竹提取物。
取80g罗汉果,粉碎后与960ml水混合,100℃提取3次,每次提取2h,合并提取液。将提取液减压浓缩至60℃相对密度为1.2的浸膏,将浸膏喷雾干燥后得到罗汉果提取物。
取150g鱼腥草与1500ml水混合,100℃提取3次,每次提取2h,合并提取液,将提取液减压浓缩至60℃相对密度为1.2的浸膏,将浸膏喷雾干燥后得到鱼腥草提取物。
取蒲公英100g粉碎后与1000ml 50vt%的乙醇溶液混合,80℃水浴加热提取4h,过滤,取滤渣。将滤渣与水按质量体积比1g:10ml的比例混合,70℃提取2次,每次提取1h,合并两次提取液,将提取液减压浓缩至60℃相对密度为1.2的浸膏,将浸膏喷雾干燥后得到蒲公英提取物。
取80g鲜白茅根,洗净切段后,加入240ml水,100℃提取3次,每次提取2h。合并提取液,将提取液减压浓缩至60℃相对密度为1.2的浸膏,将浸膏喷雾干燥后得到鲜白茅根提取物。
取120g白芷粉碎后与600ml 75vt%的乙醇溶液混合,水浴加热至75℃,提取2次,每次2h,合并提取液,将提取液减压浓缩至60℃相对密度为1.2的浸膏,将浸膏喷雾干燥后得到白芷提取物。
取淡竹叶100g与700ml水混合,100℃提取3次,每次提取2h,合并提取液液,将提取液减压浓缩至60℃相对密度为1.2的浸膏,将浸膏喷雾干燥,得到淡竹叶提取物。
取80g葛根粉碎后与640ml水混合,100℃提取2次,每次提取3h,合并提取液,将提取液减压浓缩至60℃相对密度为1.2的浸膏,将浸膏喷雾干燥,得到葛根提取物。
取40g金银花与280ml水混合,100℃提取2次,每次提取2h,合并提取液,将提取液减压浓缩至60℃相对密度为1.2的浸膏,将浸膏喷雾干燥,得到金银花提取物。
玉竹提取物、罗汉果提取物、鱼腥草提取物、蒲公英提取物、鲜白茅根提取物、白芷提取物、淡竹叶提取物、葛根提取物和金银花提取物混合,得到混合物。将混合物与水按1g:5ml的比例混合,加入适量蔗糖溶解后,过滤,取滤液灌装、灭菌,得到口服液,口服液的规格为10ml/支。
实施例3
取玉竹120g、白芷120g、罗汉果60g、鱼腥草100g、蒲公英80g、鲜白茅根100g、淡竹叶40g、金银花40g、菊花40g混合,得到混合物。将混合物与7000ml水混合,100℃提取2次,每次提取2h。合并提取液,将提取液减压浓缩至60℃相对密度为1.3的浸膏,将浸膏与适量的蔗糖、糊精混合,造粒,得到颗粒剂。颗粒剂的规格为2g/袋。
实验例1
选取某医院就诊被诊断为腺样体肥大的患者56例,年龄在3~10岁,男孩30例,女孩26例。患者的临床症状均表现出:拍鼻咽侧位片时,腺样体占鼻烟腔气道1/2以上,睡中打鼾;张口呼吸、鼻塞。将56例患者随机分成2组,每组28人,治疗组和对照组。治疗组患者服用实施例1的水煎剂,3~6岁患者2天服用1剂,每天服用3次;7~10岁患者,1d服用1剂,每天服用3次。对照组患者口服头孢克肟,按25mg/kg的剂量服用,每天3次,同时给予地奈德鼻喷雾剂。1个月后观察不同治疗组的患者的情况。
诊断标准为:X线鼻咽侧位片腺样本缩小,打鼾、张口呼吸、鼻塞情况得到改善为有效;X线鼻咽侧位片腺样本明显缩小,打鼾、张口呼吸、鼻塞情况消失为显效;X线鼻咽侧位片腺样本无变化或更大,打鼾、张口呼吸、鼻塞情况未见好转为无效。最终患者治疗情况如表1所示。
表1不同治疗方法的治疗情况
组别 | 显效数(人) | 有效数(人) | 无效数(人) | 总有效率% |
治疗组 | 16 | 11 | 1 | 96.4 |
对照组 | 6 | 10 | 12 | 57.1 |
总有效率=[(显效人数+有效人数)/总人数]×100%。
表1显示,利用实施例1的水煎剂对儿童腺样体肥大的总有效率能达到96.4%,明显高于头孢和地奈德鼻喷雾剂的治疗的效果。
观察期间,治疗组的患者未出现任何不良反应,说明实施例1的水煎剂安全有效。
对治疗组的患者又继续按上述方法进行治疗,继续跟踪随访1个月,结果发现,治疗组患者又接受治疗1个月后的显效数达到23例,其中有5例患儿的X线鼻咽侧位片腺样本已经恢复正常,无效人数2例。有效率高达100%。
实验例2
选取医院就诊诊断为腺样体肥大的患者46例,年龄在4~10岁,男孩22例,女孩24例。患者的临床症状均表现出:拍鼻咽侧位片时,腺样体占鼻烟腔气道1/2以上,睡中打鼾;张口呼吸、鼻塞。将46例患者随机分成2组,每组23人,治疗组和对照组。治疗组患者服用实施例2的口服液,每天1支,每天1次。对照组患者按25mg/kg的剂量服用头孢克肟,每天3次,同时给予地奈德鼻喷雾剂。治疗1个月后,后观察不同治疗组的患者的情况。
诊断标准如实验例1所述的标准,诊断结果如表2所示。
表2不同治疗方法的治疗情况
表2显示,利用实施例2的口服液对儿童腺样体肥大的总有效率能达到91.3%。
观察期间,治疗组的患者未出现任何不良反应,这说明实施例2的口服液安全有效。
实验例3
选取某医院就诊诊断为腺样体肥大的患者98例,年龄在3~11岁,患者的临床症状均表现出:拍鼻咽侧位片时,腺样体占鼻烟腔气道1/2以上,睡中打鼾;张口呼吸、鼻塞。将上述患者分成治疗组和对照组。治疗组50例,男26例,女24例;对照组48例,男25例,女23例。治疗组患者服用实施例3的颗粒剂,早晚各一袋,冲服。对照组患者按25mg/kg的剂量服用头孢克肟,每天3次,同时给予地奈德鼻喷雾剂。1个月后观察不同治疗组的患者的情况。
诊断标准如实验例所述的标准,诊断结果如表3所示。
表3不同治疗方法的治疗情况
组别 | 显效数(人) | 有效数(人) | 无效数(人) | 总有效率% |
治疗组 | 16 | 28 | 6 | 88 |
对照组 | 12 | 16 | 20 | 58.3 |
表3显示,利用实施例3的颗粒剂,也能有效的改善儿童腺样体肥大,有效率能达到88%。
观察期间,治疗组的患者未发现不良反应,说明实施例3的颗粒剂安全有效。
应用实施例1
张某某,男,4岁,就诊时鼻咽侧位片的拍摄结果为:腺样本占鼻烟腔气道的3/4,睡觉打鼾,张口呼吸、鼻塞严重,伴鼻窦炎和听力障碍,被判定为重度腺样体肥大症。该患儿利用实施例1的水煎剂进行治疗,2天服用1剂,每天服用3次。接受治疗1个月后复查鼻咽侧位片发现,腺样本占鼻烟腔气道的2/3,腺样本明显缩小,听力也得到了一定的恢复。又继续接受治疗1个月后复查,腺样本占鼻烟腔气道1/2~2/3,鼻窦炎消失,听力障碍消失,轻微鼻塞,打鼾情况也得到改善。接受治疗3个月后,腺样本占鼻烟腔气道恢复至1/2以下,达到正常标准,鼻塞消失,偶尔打鼾,临床断定治愈。家长为了巩固,又继续接受治疗1个月,上述症状完全消失。
应用实施例2
李某某,女,6岁,就诊时鼻咽侧位片的拍摄结果为:腺样本占鼻烟腔气道的2/3~3/4,睡觉打鼾,张口呼吸、鼻塞严重,被判定为中度腺样体肥大症。该患儿利用实施例3的颗粒剂进行治疗,早晚各一袋,冲服。接受治疗1个月后复查鼻咽侧位片发现,腺样本占鼻烟腔气道的1/2~2/3,腺样本明显缩小,打鼾情况得到改善,鼻塞消失,闭口呼吸。继续治疗1个月,腺样本占鼻烟腔气道1/2以下,达到撑场标准,打鼾也消失。
由以上实施例可知,本发明提供了一种改善儿童腺样体肥大的中药组合物及其应用与水煎剂、口服液和颗粒剂。按照本发明中药组合物配伍得到的组分制备得到的药物来改善儿童腺样体肥大,有效率能达到88%以上。较现有技术利用抗生素,同时配合地奈德鼻喷雾剂的治疗效果的有效率至少高29.7个百分点,较手术治疗更为安全,为儿童腺样本肥大的治疗提供依据,具有推广应用价值。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (9)
1.一种改善儿童腺样体肥大的中药组合物,其特征在于,包括如下质量份数的组分:
玉竹8~15份、白芷10~14份、罗汉果6~8份、鱼腥草10~15份、蒲公英6~10份、鲜白茅根8~15份、淡竹叶5~10份。
2.根据权利要求1所述的中药组合物,其特征在于,包括如下质量份数的组分:
玉竹10~13份、白芷11~13份、罗汉果6.5~7.5份、鱼腥草11~14份、蒲公英7~9份、鲜白茅根10~13份、淡竹叶6~9份。
3.根据权利要求2所述的中药组合物,其特征在于,包括如下质量份数的组分:
玉竹11.5份、白芷12份、罗汉果7份、鱼腥草12.5份、蒲公英8份、鲜白茅根11.5份、淡竹叶7.5份。
4.根据权利要求1~3任意一项所述的中药组合物,其特征在于,还包括如下组分中的任意一种或多种:
甘草、桑叶、葛根、金银花和菊花;
甘草、桑叶、葛根、金银花和菊花的加量独立为2~8份。
5.权利要求1~4任意一项所述的中药组合物在制备改善儿童腺样体肥大的药物中的应用。
6.根据权利要求5所述的应用,其特征在于,所述药物的剂型为水煎剂、口服液或颗粒剂。
7.一种改善儿童腺样体肥大的水煎剂,其特征在于,所述水煎剂由权利要求1~4任意一项所述的中药组合物制备而成;
所述水煎剂的制备方法包括如下步骤:
将玉竹、白芷、罗汉果、鱼腥草、蒲公英、鲜白茅根、淡竹叶、桑叶和甘草混合,得到混合物;将所述的混合物与水混合,煎煮1.5~2.5h,过滤,取滤液,得到水煎剂;
所述混合物与水混合的质量比为1:7~9。
8.一种改善儿童腺样体肥大的口服液,其特征在于,所述口服液由权利要求1~4任意一项所述的中药组合物制备而成;
所述口服液的制备方法包括如下步骤:
(1)将玉竹与水混合,95~100℃提取1~3次,合并提取液,将所述的提取液浓缩至原体积的1/5~1/4,得到浓缩物;将所述的浓缩物与无水乙醇混合,静置10~14h,过滤,取沉淀;淋洗所述的沉淀2~4次后,干燥,得玉竹提取物;
(2)将罗汉果与水混合,95~100℃提取1~3次,合并提取液,将所述的提取液浓缩至60℃相对密度为1.2~1.3,得到浸膏,将所述的浸膏喷雾干燥,得到罗汉果提取物;
(3)将鱼腥草与水混合,95~100℃提取2~4次,合并提取液,将所述的提取液浓缩至60℃相对密度为1.2~1.3,得到浸膏,将所述的浸膏喷雾干燥,得到鱼腥草提取物;
(4)将蒲公英与乙醇溶液混合,加热提取3~5h,过滤,取滤渣;将所述的滤渣与水混合,提取1~3次,合并提取液,将所述的提取液浓缩至60℃相对密度为1.1~1.2的浸膏,将所述的浸膏喷雾干燥,得到蒲公英提取物;
(5)将鲜白茅根与水混合,95~100℃提取2~4次,合并提取液,将所述的提取液浓缩至60℃相对密度为1.1~1.2的浸膏,将所述的浸膏喷雾干燥,得到鲜白茅根提取物;
(6)将白芷与乙醇溶液混合,加热提取1~3次,合并提取液,将所述的提取液浓缩至60℃相对密度为1.1~1.2的浸膏,将所述的浸膏喷雾干燥,得到白芷提取物;
(7)将淡竹叶与水混合,95~100℃提取2~4次,合并提取液,将所述的提取液浓缩至60℃相对密度为1.1~1.2的浸膏,将所述的浸膏喷雾干燥,得到淡竹叶提取物;
(8)将葛根与水混合,95~100℃提取1~3次,合并提取液,将所述的提取液浓缩至60℃相对密度为1.2~1.3,得到浸膏,将所述的浸膏喷雾干燥,得到葛根提取物;
(9)将金银花与水混合,95~100℃提取1~3次,合并提取液,将所述的提取液浓缩至60℃相对密度为1.2~1.3,得到浸膏,将所述的浸膏喷雾干燥,得到金银花提取物;
(10)将所述的玉竹提取物、罗汉果提取物、鱼腥草提取物、蒲公英提取物、鲜白茅根提取物、白芷提取物、淡竹叶提取物、葛根提取物和金银花提取物混合,得到混合物,将所述的混合物与水混合,过滤,取滤液,得到口服液;
步骤(1)所述玉竹与水混合的质量体积比为1g:9~11ml;步骤(1)所述提取时,每次提取的时间为3~5h;步骤(1)所述浓缩物与无水乙醇混合的体积比为1:3~5;
步骤(2)所述罗汉果与水混合的质量体积比为1g:10~14ml;步骤(2)所述提取时,每次提取的时间为1.8~2.2h;
步骤(3)所述鱼腥草与水混合的质量体积比为1g:9~11ml;步骤(3)所述提取时,每次提取的时间为1.8~2.2h;
步骤(4)所述蒲公英与乙醇溶液混合的质量体积比为1g:9~11ml;所述乙醇溶液的初始浓度为45~55vt%;步骤(4)所述加热提取的温度为75~85℃;所述滤渣与水混合的质量体积比为1g:9~11ml;步骤(4)所述提取的温度为65~75℃;步骤(4)所述提取时,每次提取的时间为0.8~1.2h;
步骤(5)所述鲜白茅根与水混合的质量体积比为1g:2~4ml;步骤(5)所述提取时,每次提取的时间为1.8~2.2h;
步骤(6)所述白芷与乙醇溶液混合的质量体积比为1g:4~6ml;步骤(6)所述乙醇溶液的初始浓度为70~80vt%;步骤(6)所述加热提取的温度为70~80℃;步骤(6)所述加热提取时,每次提取的时间为1.8~2.2h;
步骤(7)所述淡竹叶与水混合的质量体积比为1g:6~8mL;步骤(7)所述提取时,每次提取的时间为2~3h;
步骤(8)所述葛根与水混合的质量体积比为1g:7~9ml;步骤(8)所述提取时,每次提取的时间为2.5~3.5h;
步骤(9)所述金银花与水混合的质量体积比为1g:6~8ml;步骤(9)所述提取时,每次提取的时间为1.5~2.5h;
步骤(10)所述混合物与水混合的质量体积比为1g:4~6ml。
9.一种改善儿童腺样体肥大的颗粒剂,其特征在于,所述颗粒剂由权利要求1~4任意一项所述的中药组合物制备而成;
所述颗粒剂的制备方法包括如下步骤:
将玉竹、白芷、罗汉果、鱼腥草、蒲公英、鲜白茅根、淡竹叶、金银花和菊花混合,得到混合物;将所述的混合物与水混合,95~100℃提取2~4次,合并提取液;将所述的提取液浓缩至60℃相对密度为1.2~1.3的浸膏,将所述的浸膏与药学上可接受的辅料混合,得到颗粒剂;
所述混合物与水混合的质量体积比为1g:9~11ml;所述提取时,每次提取的时间为1.8~2.2h。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311491496.2A CN117357614A (zh) | 2023-11-09 | 2023-11-09 | 一种改善儿童腺样体肥大的中药组合物及其应用与水煎剂、口服液和颗粒剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311491496.2A CN117357614A (zh) | 2023-11-09 | 2023-11-09 | 一种改善儿童腺样体肥大的中药组合物及其应用与水煎剂、口服液和颗粒剂 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117357614A true CN117357614A (zh) | 2024-01-09 |
Family
ID=89392852
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311491496.2A Pending CN117357614A (zh) | 2023-11-09 | 2023-11-09 | 一种改善儿童腺样体肥大的中药组合物及其应用与水煎剂、口服液和颗粒剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117357614A (zh) |
-
2023
- 2023-11-09 CN CN202311491496.2A patent/CN117357614A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102198236B (zh) | 一种治疗急性鼻窦炎的中药组合物及其制备方法 | |
CN111214566A (zh) | 一种防疫中药组合物及其制备方法和应用 | |
WO2021208335A1 (zh) | 解毒化湿利咽中药组合物及其应用 | |
WO2021179505A1 (zh) | 一种翘芪复方制剂及其制备方法和用途 | |
CN104887952B (zh) | 一种具有养阴润肺作用的组合物及其制备方法和应用 | |
CN109908194B (zh) | 一种用于治疗急慢性咽炎的药物及其制备方法 | |
CN103977314A (zh) | 一种治疗呼吸道疾病的药物组合物及制备方法和用途 | |
CN107158223A (zh) | 用于清热解毒与消炎的中药制剂及其制备方法 | |
CN104940485A (zh) | 一种治疗小儿哮喘的中药组合物及其制备方法 | |
CN107625828A (zh) | 一种用于辅助治疗慢性咽炎的保健茶、制备方法及应用 | |
CN116139237B (zh) | 一种防治新型冠状病毒等所致呼吸道感染的中药组合物及其应用 | |
CN105456818A (zh) | 一种含有艾叶的治疗失眠的中药组合物及其制备方法 | |
CN105055841A (zh) | 一种治疗慢性咽炎的药物及其制备方法 | |
CN102552509A (zh) | 清热止咳中药组合物 | |
CN101708207B (zh) | 一种祛痰止咳药物组合物及其制备方法 | |
CN100430085C (zh) | 一种治疗清扫宣肺、化痰止咳的药物及其制备方法 | |
CN117357614A (zh) | 一种改善儿童腺样体肥大的中药组合物及其应用与水煎剂、口服液和颗粒剂 | |
CN103405722B (zh) | 一种预防和治疗小儿咳嗽的中药制剂 | |
CN102626511B (zh) | 一种用于止咳祛痰的药物组合物 | |
CN107158286B (zh) | 一种用于治疗雾霾致呼吸道损伤诱发症的中药组合物及其制备方法 | |
CN105233252A (zh) | 一种治疗急性化脓性胆管炎的中西药复方制剂 | |
CN110742923A (zh) | 一种治疗产妇拘乳的中药组合物、中药制剂及其制备方法 | |
CN109663012A (zh) | 疏风清热,解毒利咽中药组合物及其制备方法与应用 | |
CN112494598B (zh) | 一种用于治疗咽炎的有效部位组合物及其应用 | |
CN104667247A (zh) | 一种治疗咳嗽的中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |